“Among several commercial services who have claimed to be specialized to generate mouse models with genetic modifications, I recognize that Cyagen is one of the best. We are looking forward to having more cooperation with them.”Korea Brain Research Institute (KBRI)
영업일 기준 1-2일 내에 답변해 드리겠습니다.
Strain Background: C57BL/6N
The humanized OX40 mouse model (hOX40) is developed by Knockin at the mouse OX40 locus and expresses a fully humanized OX40 protein with a human extracellular, human transmembrane and murine intracellular domain.
Research and Application:
The hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint (ICP) OX40 in fully immunocompetent mice.
Figure 1. hOX40 expression pattern in hOX40 mice recapitulates mOX40 in WT mice. hOX40 and mOX40 expression on splenocytes activated with αCD3/αCD28 in presence of mIL-2: on (A) Tregs (viable, CD3+CD4+CD25+FoxP3+), (B) conventional CD4+ (viable, CD3+CD4+FoxP3- ), and (C) CD8+ (viable, CD3+CD8+) T cells at day 3 of culture. Kinetic of hOX40 and mOX40 expression on (D) Treg and (E) conventional CD4 and (F) CD8 T cells. Results are expressed as mean±SD.
Figure 2. hOX40 is functional on effector T cells ex vivo. Splenic and LN-isolated T cells (CD8+) activated with αCD3/αCD28 and immobilized hOX40L or IgG-Fc - it can be seen that hOX40L treatment significantly promoted the proliferation of T cells (CD8+) and the secretion of IFN in hOX40 mice. (A) Flow chart. (B) Representative histogram and (C) mIFN-γ production measured by ELISA in culture supernatant.
Figure 3. In vivo anti-tumor activity is observed in response to ahOX40. hOX40 mice bearing MC38 tumor were treated with ahOX40 (BMS-986178 analog). The proliferation of tumor was significantly inhibited compared to the control.